To determine whether rimantadine can protect family members from acquiring influenza A viral illness and to assess the possible selection of drug-resistant strains of virus, we conducted a randomized, double-blind, placebo-controlled study in three communities during two influenza seasons. When influenza A occurred in a family, the members (including the index patient) were given either rimantadine (adult oral dose, 200 mg per day) or placebo for 10 days. The presence of illness was monitored by daily recording of symptoms and temperature measurements; infection was determined by isolation of the virus and by serologic studies. Among households with documented influenza A infections, symptomatic illness occurred in one or more contacts in 10 of 28 families treated with rimantadine and in 10 of 209 families treated with placebo. Asymptomatic secondary influenza A infections were found in five families assigned to receive rimantadine and in four families assigned to receive placebo. Rimantadine-resistant strains of influenza A virus (H3N2 subtype) with mutations consisting of single amino acid changes in the M2 protein (residue 27, 30, or 31) were recovered from eight index patients and five contacts treated with rimantadine. There was apparent transmission of drug-resistant strains of virus in six contacts with secondary illnesses in five families. We conclude that when index patients are treated concurrently, rimantadine is ineffective in protecting household members from influenza A infection. If rimantadine is used for both treatment and postexposure prophylaxis in families, rapid selection and apparent transmission of drug-resistant influenza A viruses can occur.
Source Information
University of Virginia, Charlottesville.
This article has been cited by other articles:
Lee, J., Song, Y. J., Park, J. H., Lee, J.-H., Baek, Y. H., Song, M.-S., Oh, T.-K., Han, H.-S., Pascua, P. N. Q., Choi, Y.-K.
(2008). Emergence of Amantadine-Resistant H3N2 Avian Influenza A Virus in South Korea. J. Clin. Microbiol.
46: 3788-3790
[Abstract][Full Text]
Yen, H.-L., Ilyushina, N. A., Salomon, R., Hoffmann, E., Webster, R. G., Govorkova, E. A.
(2007). Neuraminidase Inhibitor-Resistant Recombinant A/Vietnam/1203/04 (H5N1) Influenza Viruses Retain Their Replication Efficiency and Pathogenicity In Vitro and In Vivo. J. Virol.
81: 12418-12426
[Abstract][Full Text]
Lim, W S
(2007). Pandemic flu: clinical management of patients with an influenza-like illness during an influenza pandemic. Thorax
62: 1-46
[Full Text]
Monto, A. S., McKimm-Breschkin, J. L., Macken, C., Hampson, A. W., Hay, A., Klimov, A., Tashiro, M., Webster, R. G., Aymard, M., Hayden, F. G., Zambon, M.
(2006). Detection of Influenza Viruses Resistant to Neuraminidase Inhibitors in Global Surveillance during the First 3 Years of Their Use.. Antimicrob. Agents Chemother.
50: 2395-2402
[Abstract][Full Text]
Weinstock, D. M., Zuccotti, G.
(2006). Adamantane Resistance in Influenza A. JAMA
295: 934-936
[Full Text]
Bright, R. A., Shay, D. K., Shu, B., Cox, N. J., Klimov, A. I.
(2006). Adamantane Resistance Among Influenza A Viruses Isolated Early During the 2005-2006 Influenza Season in the United States. JAMA
295: 891-894
[Abstract][Full Text]
Yen, H.-L., Herlocher, L. M., Hoffmann, E., Matrosovich, M. N., Monto, A. S., Webster, R. G., Govorkova, E. A.
(2005). Neuraminidase Inhibitor-Resistant Influenza Viruses May Differ Substantially in Fitness and Transmissibility. Antimicrob. Agents Chemother.
49: 4075-4084
[Abstract][Full Text]
Teo, S S S, Nguyen-Van-Tam, J S, Booy, R
(2005). Influenza burden of illness, diagnosis, treatment, and prevention: what is the evidence in children and where are the gaps?. Arch. Dis. Child.
90: 532-536
[Abstract][Full Text]
McKimm-Breschkin, J., Trivedi, T., Hampson, A., Hay, A., Klimov, A., Tashiro, M., Hayden, F., Zambon, M.
(2003). Neuraminidase Sequence Analysis and Susceptibilities of Influenza Virus Clinical Isolates to Zanamivir and Oseltamivir. Antimicrob. Agents Chemother.
47: 2264-2272
[Abstract][Full Text]
Saito, R., Sakai, T., Sato, I., Sano, Y., Oshitani, H., Sato, M., Suzuki, H.
(2003). Frequency of Amantadine-Resistant Influenza A Viruses during Two Seasons Featuring Cocirculation of H1N1 and H3N2. J. Clin. Microbiol.
41: 2164-2165
[Abstract][Full Text]
Ferguson, N. M., Mallett, S., Jackson, H., Roberts, N., Ward, P.
(2003). A population-dynamic model for evaluating the potential spread of drug-resistant influenza virus infections during community-based use of antivirals. J Antimicrob Chemother
51: 977-990
[Abstract][Full Text]
Stiver, G.
(2003). The treatment of influenza with antiviral drugs. CMAJ
168: 49-57
[Abstract][Full Text]
Furuta, Y., Takahashi, K., Fukuda, Y., Kuno, M., Kamiyama, T., Kozaki, K., Nomura, N., Egawa, H., Minami, S., Watanabe, Y., Narita, H., Shiraki, K.
(2002). In Vitro and In Vivo Activities of Anti-Influenza Virus Compound T-705. Antimicrob. Agents Chemother.
46: 977-981
[Abstract][Full Text]
Kati, W. M., Montgomery, D., Carrick, R., Gubareva, L., Maring, C., McDaniel, K., Steffy, K., Molla, A., Hayden, F., Kempf, D., Kohlbrenner, W.
(2002). In Vitro Characterization of A-315675, a Highly Potent Inhibitor of A and B Strain Influenza Virus Neuraminidases and Influenza Virus Replication. Antimicrob. Agents Chemother.
46: 1014-1021
[Abstract][Full Text]
Guo, C.-T., Sun, X.-L., Kanie, O., Shortridge, K. F., Suzuki, T., Miyamoto, D., Hidari, K. I.-P. J., Wong, C.-H., Suzuki, Y.
(2002). An O-glycoside of sialic acid derivative that inhibits both hemagglutinin and sialidase activities of influenza viruses. Glycobiology
12: 183-190
[Abstract][Full Text]
Saito, R., Oshitani, H., Masuda, H., Suzuki, H.
(2002). Detection of Amantadine-Resistant Influenza A Virus Strains in Nursing Homes by PCR-Restriction Fragment Length Polymorphism Analysis with Nasopharyngeal Swabs. J. Clin. Microbiol.
40: 84-88
[Abstract][Full Text]
Ahmed, F., Singleton, J. A., Franks, A. L.
(2001). Influenza Vaccination for Healthy Young Adults. NEJM
345: 1543-1547
[Full Text]
Luce, B. R., Zangwill, K. M., Palmer, C. S., Mendelman, P. M., Yan, L., Wolff, M. C., Cho, I., Marcy, S. M., Iacuzio, D., Belshe, R. B.
(2001). Cost-Effectiveness Analysis of an Intranasal Influenza Vaccine for the Prevention of Influenza in Healthy Children. Pediatrics
108
: e24-e24
[Abstract][Full Text]
Stephenson, I., Nicholson, K.G.
(2001). Influenza: vaccination and treatment. Eur Respir J
17: 1282-1293
[Abstract][Full Text]
Iwahashi, J., Tsuji, K., Ishibashi, T., Kajiwara, J., Imamura, Y., Mori, R., Hara, K., Kashiwagi, T., Ohtsu, Y., Hamada, N., Maeda, H., Toyoda, M., Toyoda, T.
(2001). Isolation of Amantadine-Resistant Influenza A Viruses (H3N2) from Patients following Administration of Amantadine in Japan. J. Clin. Microbiol.
39: 1652-1653
[Abstract][Full Text]
Welliver, R., Monto, A. S., Carewicz, O., Schatteman, E., Hassman, M., Hedrick, J., Jackson, H. C., Huson, L., Ward, P., Oxford, J. S., for the Oseltamivir Post Exposure Prophylaxis Inve,
(2001). Effectiveness of Oseltamivir in Preventing Influenza in Household Contacts: A Randomized Controlled Trial. JAMA
285: 748-754
[Abstract][Full Text]
Shulman, S. T.
(2001). Zanamivir Prevents Secondary Cases of Influenza in Healthy Household Contacts. AAP Grand Rounds
5: 2-3
[Full Text]
Couch, R. B.
(2000). Influenza: Prospects for Control. ANN INTERN MED
133: 992-998
[Abstract][Full Text]
Couch, R. B.
(2000). Prevention and Treatment of Influenza. NEJM
343: 1778-1787
[Full Text]
Cifu, A., Levinson, W.
(2000). Influenza. JAMA
284: 2847-2849
[Full Text]
Hayden, F. G., Gubareva, L. V., Monto, A. S., Klein, T. C., Elliott, M. J., Hammond, J. M., Sharp, S. J., Ossi, M. J., The Zanamivir Family Study Group,
(2000). Inhaled Zanamivir for the Prevention of Influenza in Families. NEJM
343: 1282-1289
[Abstract][Full Text]
Treanor, J. J., Hayden, F. G., Vrooman, P. S., Barbarash, R., Bettis, R., Riff, D., Singh, S., Kinnersley, N., Ward, P., Mills, R. G., for the US Oral Neuraminidase Study Group,
(2000). Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza: A Randomized Controlled Trial. JAMA
283: 1016-1024
[Abstract][Full Text]
Wenzel, R. P.
(2000). Expanding the Treatment Options for Influenza. JAMA
283: 1057-1059
[Full Text]
Barnett, J. M., Cadman, A., Gor, D., Dempsey, M., Walters, M., Candlin, A., Tisdale, M., Morley, P. J., Owens, I. J., Fenton, R. J., Lewis, A. P., Claas, E. C. J., Rimmelzwaan, G. F., De Groot, R., Osterhaus, A. D. M. E.
(2000). Zanamivir Susceptibility Monitoring and Characterization of Influenza Virus Clinical Isolates Obtained during Phase II Clinical Efficacy Studies. Antimicrob. Agents Chemother.
44: 78-87
[Abstract][Full Text]
Monto, A. S., Robinson, D. P., Herlocher, M. L., Hinson, J. M. Jr, Elliott, M. J., Crisp, A.
(1999). Zanamivir in the Prevention of Influenza Among Healthy Adults: A Randomized Controlled Trial. JAMA
282: 31-35
[Abstract][Full Text]
Stephenson, I., Nicholson, K. G.
(1999). Chemotherapeutic control of influenza. J Antimicrob Chemother
44: 6-10
[Full Text]
White, T., Lavoie, S., Nettleman, M. D.
(1999). Potential Cost Savings Attributable to Influenza Vaccination of School-aged Children. Pediatrics
103: 73e-73
[Abstract][Full Text]
Balfour, H. H.
(1999). Antiviral Drugs. NEJM
340: 1255-1268
[Full Text]
Drinka, P. J., Gravenstein, S., Schilling, M., Krause, P., Miller, B. A., Shult, P.
(1998). Duration of Antiviral Prophylaxis During Nursing Home Outbreaks of Influenza A: A Comparison of 2 Protocols. Arch Intern Med
158: 2155-2159
[Abstract][Full Text]
Pillay, D., Zambon, M.
(1998). Antiviral drug resistance. BMJ
317: 660-662
[Full Text]
Pillay, D., Geddes, A. M
(1996). Antiviral drug resistance. BMJ
313: 503-504
[Full Text]
Houck, P., Hemphill, M., LaCroix, S., Hirsh, D., Cox, N.
(1995). Amantadine-Resistant Influenza A in Nursing Homes: Identification of a Resistant Virus Prior to Drug Use. Arch Intern Med
155: 533-537
[Abstract]
Degelau, J., Somani, S. K., Cooper, S. L., Guay, D. R. P., Crossley, K. B.
(1992). Amantadine-Resistant Influenza A in a Nursing Facility. Arch Intern Med
152: 390-392
[Abstract]
Previous
